OLIG1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8TAK6 |
---|---|
Clone Names | 90415119 |
Gene ID | 116448 |
---|---|
Other Names | Oligodendrocyte transcription factor 1, Oligo1, Class B basic helix-loop-helix protein 6, bHLHb6, Class E basic helix-loop-helix protein 21, bHLHe21, OLIG1, BHLHB6, BHLHE21 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | OLIG1 |
---|---|
Synonyms | BHLHB6, BHLHE21 |
Function | Promotes formation and maturation of oligodendrocytes, especially within the brain. Cooperates with OLIG2 to establish the pMN domain of the embryonic neural tube (By similarity). |
Cellular Location | Nucleus {ECO:0000255|PROSITE-ProRule:PRU00981}. |
Tissue Location | Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas is highly variable. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
OLIG1 promotes formation and maturation of oligodendrocytes, especially within the brain. Cooperates with OLIG2 to establish the pMN domain of the embryonic neural tube (By similarity).
References
Takei, H., et al. J. Neurooncol. 86(2):183-190(2008)Ruf, N., et al. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (3), 365-366 (2007) :Brena, R.M., et al. PLoS Med. 4 (3), E108 (2007) :Stewart, S.E., et al. Arch. Gen. Psychiatry 64(2):209-214(2007)Goris, A., et al. J. Neurol. Neurosurg. Psychiatr. 77(11):1296-1297(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.